دورية أكاديمية
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
العنوان: | Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. |
---|---|
المؤلفون: | Tate SC; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and tate_sonya@network.lilly.com., Cai S; Eli Lilly and Company, Indianapolis, Indiana., Ajamie RT; Eli Lilly and Company, Indianapolis, Indiana., Burke T; Eli Lilly and Company, Indianapolis, Indiana., Beckmann RP; Eli Lilly and Company, Indianapolis, Indiana., Chan EM; Eli Lilly and Company, Indianapolis, Indiana., De Dios A; Eli Lilly and Company, Indianapolis, Indiana., Wishart GN; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and., Gelbert LM; Eli Lilly and Company, Indianapolis, Indiana., Cronier DM; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and. |
المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Jul 15; Vol. 20 (14), pp. 3763-74. Date of Electronic Publication: 2014 May 21. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
مواضيع طبية MeSH: | Aminopyridines/*pharmacokinetics , Antineoplastic Agents/*pharmacokinetics , Benzimidazoles/*pharmacokinetics, Administration, Oral ; Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Humans ; Inhibitory Concentration 50 ; Mice, Nude ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays |
مستخلص: | Purpose: Selective inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) represents a promising therapeutic strategy. However, despite documented evidence of clinical activity, limited information is available on the optimal dosing strategy of CDK4/6 inhibitors. Here, we present an integrated semi-mechanistic pharmacokinetic/pharmacodynamic model to characterize the quantitative pharmacology of LY2835219, a CDK4/6 inhibitor, in xenograft tumors. Experimental Design: LY2835219 plasma concentrations were connected to CDK4/6 inhibition and cell-cycle arrest in colo-205 human colorectal xenografts by incorporating the biomarkers, phospho-(ser780)-Rb, topoisomerase II α, and phosphohistone H3, into a precursor-dependent transit compartment model. This biomarker model was then connected to tumor growth inhibition (TGI) by: (i) relating the rate of tumor growth to mitotic cell density, and (ii) incorporating a concentration-dependent mixed cytostatic/cytotoxic effect driving quiescence and cell death at high doses. Model validation was evaluated by predicting LY2835219-mediated antitumor effect in A375 human melanoma xenografts. Results: The model successfully described LY2835219-mediated CDK4/6 inhibition, cell-cycle arrest, and TGI in colo-205, and was validated in A375. The model also demonstrated that a chronic dosing strategy achieving minimum steady-state trough plasma concentrations of 200 ng/mL is required to maintain durable cell-cycle arrest. Quiescence and cell death can be induced by further increasing LY2835219 plasma concentrations. Conclusions: Our model provides mechanistic insight into the quantitative pharmacology of LY2835219 and supports the therapeutic dose and chronic dosing strategy currently adopted in clinical studies. (©2014 American Association for Cancer Research.) |
المشرفين على المادة: | 0 (Aminopyridines) 0 (Antineoplastic Agents) 0 (Benzimidazoles) 0 (Biomarkers, Tumor) 0 (Protein Kinase Inhibitors) 60UAB198HK (abemaciclib) EC 2.7.11.22 (CDK4 protein, human) EC 2.7.11.22 (CDK6 protein, human) EC 2.7.11.22 (Cyclin-Dependent Kinase 4) EC 2.7.11.22 (Cyclin-Dependent Kinase 6) |
تواريخ الأحداث: | Date Created: 20140523 Date Completed: 20150904 Latest Revision: 20191210 |
رمز التحديث: | 20221213 |
DOI: | 10.1158/1078-0432.CCR-13-2846 |
PMID: | 24850847 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1557-3265 |
---|---|
DOI: | 10.1158/1078-0432.CCR-13-2846 |